Valeurs | |||||
Le rangement donne un aperçu de toutes les valeurs mobilières classées de manière alphabétique ou selon les indices. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Nom | Code | Analysis date | Cours de clôture | +/- % |
Customers Bancorp | CUBI | 24. mar 2025 | 52.77 | +2.37 |
Customers Bancorp E Pref | CUBI-E | 24. mar 2025 | 25.61 | -0.25 |
Customers Bancorp F Pref | CUBI-F | 24. mar 2025 | 25.31 | -0.12 |
Cutera | CUTR | 24. mar 2025 | 0.11 | 0.00 |
CVB Financial | CVBF | 24. mar 2025 | 19.12 | +2.25 |
CVD Equipment | CVV | 24. mar 2025 | 3.15 | +2.36 |
CVR Energy | CVI | 24. mar 2025 | 20.29 | -4.29 |
Cvr Partners LP Unit | UAN | 24. mar 2025 | 75.72 | +0.45 |
CVRx | CVRX | 24. mar 2025 | 12.76 | +2.16 |
CVS Health | CVS | 24. mar 2025 | 67.57 | +0.78 |
CXApp A | CXAI | 24. mar 2025 | 0.96 | +0.45 |
CyberArk Software | CYBR | 24. mar 2025 | 351.00 | -0.22 |
Cybin | CYBN | 24. mar 2025 | 7.38 | +0.96 |
Cyclacel Pharmaceuticals | CYCC | 24. mar 2025 | 0.32 | +1.25 |
Cyclacel Pharmaceuticals Pref | CYCCP | 24. mar 2025 | 6.00 | -2.60 |
Cyclerion Therapeutics | CYCN | 24. mar 2025 | 2.82 | +2.55 |
Cyclo Therapeutics | CYTH | 24. mar 2025 | 0.71 | +1.53 |
Cycurion | CYCU | 24. mar 2025 | 0.66 | 0.00 |
Cyngn | CYN | 24. mar 2025 | 4.98 | +9.21 |
Cytek Biosciences | CTKB | 24. mar 2025 | 4.22 | +0.48 |
Cytokinetics | CYTK | 24. mar 2025 | 46.57 | +2.51 |
Cytomed Therapeutics | GDTC | 24. mar 2025 | 2.66 | +1.92 |
CytomX Therapeutics | CTMX | 24. mar 2025 | 0.67 | +0.45 |
Cytosorbents | CTSO | 24. mar 2025 | 1.03 | +4.73 |
D-MARKET Electronic Services & Trading ADR | HEPS | 24. mar 2025 | 3.04 | +8.57 |
D-Wave Quantum | QBTS | 24. mar 2025 | 8.72 | +4.31 |
D.R. Horton | DHI | 24. mar 2025 | 130.35 | +1.17 |
Dada Nexus ADR | DADA | 24. mar 2025 | 1.88 | +1.08 |
Daily Journal | DJCO | 24. mar 2025 | 411.96 | +3.82 |
Dakota Gold | DC | 24. mar 2025 | 2.77 | -1.07 |
|
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.